Study identifier:SD-039-0717
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A 12 week, Randomized, Double-blind, Double-dummy, Placebo-controlled trial of Symbicort TM (160/4.5mcg) versus its Mono-products (budesonide and formoterol) in adolescents (at least 12 years of age) and adults with asthma - SPRUCE 160/4.5
asthma
Phase 3
No
budesonide/formoterol, budesonide, formoterol
All
450
Interventional
12 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 | - |
Active Comparator: 2 budesonide | - |
Active Comparator: 3 formoterol | - |